

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

July 4, 2022

Midazolam and Milrinone Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to production delays, our Midazolam Injection 1 mg/mL MD Vial 5 mL, Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL and 20 mL will be placed on allocation effective July 4, 2022. Contract customers will be allocated 100% of historical monthly demand.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Allocation Date
02242904	C410105	922547	22877	Midazolam Injection 1 mg/mL MD Vial 5 mL	On 100% Allocation Jul. 4, 2022
02244622	C601710	922596	3087	Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL	On 100% Allocation Jul. 4, 2022
02244622	C601720	922602	2915	Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL	On 100% Allocation Jul. 4, 2022

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

George Shamsoun

Associate Director – Marketing, IV Drugs george.shamsoun@fresenius-kabi.com